Advertisement

Topics

AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action

05:27 EDT 26 Mar 2019 | SCRIP

First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.

      

Related Stories

 

Original Article: AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action

NEXT ARTICLE

More From BioPortfolio on "AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...